Real-world use of once-weekly semaglutide in patients with type 2 diabetes: results from the SURE Switzerland multicentre, prospective, observational study

The prevalence of diabetes in Switzerland has been reported to be in the range of 4% to 7.7% [1 –3], with the majority of cases being type 2 diabetes (T2D) [4]. Treatment guidelines emphasise the need to treat T2D optimally, and the importance of reducing the longer-term cardiovascular (CV) burden of the condition has been demonstrated by the prevalence of established CV disease (CVD) in rea l-world studies such as CAPTURE [4,5].
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research